Peak width of skeletonized mean diffusivity in cerebral amyloid angiopathy: Spatial signature, cognitive, and neuroimaging associations.
cerebral amyloid angiopathy
cerebral small vessel disease
dementia
diffusion tensor imaging
diffusion-weighted imaging
vascular cognitive impairment
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
09
2022
accepted:
25
10
2022
entrez:
28
11
2022
pubmed:
29
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
Peak width of skeletonized mean diffusivity (PSMD) is a promising diffusion tensor imaging (DTI) marker that shows consistent and strong cognitive associations in the context of different cerebral small vessel diseases (cSVD). Investigate whether PSMD (1) is higher in patients with Cerebral Amyloid Angiopathy (CAA) than those with arteriolosclerosis; (2) can capture the anteroposterior distribution of CAA-related abnormalities; (3) shows similar neuroimaging and cognitive associations in comparison to other classical DTI markers, such as average mean diffusivity (MD) and fractional anisotropy (FA). We analyzed cross-sectional neuroimaging and neuropsychological data from 90 non-demented memory-clinic subjects from a single center. Based on MRI findings, we classified them into probable-CAA (those that fulfilled the modified Boston criteria), subjects with MRI markers of cSVD not attributable to CAA (presumed arteriolosclerosis; cSVD), and subjects without evidence of cSVD on MRI (non-cSVD). We compared total and lobe-specific (frontal and occipital) DTI metrics values across the groups. We used linear regression models to investigate how PSMD, MD, and FA correlate with conventional neuroimaging markers of cSVD and cognitive scores in CAA. PSMD was comparable in probable-CAA (median 4.06 × 10 PSMD is a promising biomarker of cognitive impairment in CAA that outperforms other conventional and DTI-based neuroimaging markers. Although global PSMD is similarly increased in different forms of cSVD, PSMD's spatial variations could potentially provide insights into the predominant type of underlying microvascular pathology.
Sections du résumé
Background
UNASSIGNED
Peak width of skeletonized mean diffusivity (PSMD) is a promising diffusion tensor imaging (DTI) marker that shows consistent and strong cognitive associations in the context of different cerebral small vessel diseases (cSVD).
Purpose
UNASSIGNED
Investigate whether PSMD (1) is higher in patients with Cerebral Amyloid Angiopathy (CAA) than those with arteriolosclerosis; (2) can capture the anteroposterior distribution of CAA-related abnormalities; (3) shows similar neuroimaging and cognitive associations in comparison to other classical DTI markers, such as average mean diffusivity (MD) and fractional anisotropy (FA).
Materials and methods
UNASSIGNED
We analyzed cross-sectional neuroimaging and neuropsychological data from 90 non-demented memory-clinic subjects from a single center. Based on MRI findings, we classified them into probable-CAA (those that fulfilled the modified Boston criteria), subjects with MRI markers of cSVD not attributable to CAA (presumed arteriolosclerosis; cSVD), and subjects without evidence of cSVD on MRI (non-cSVD). We compared total and lobe-specific (frontal and occipital) DTI metrics values across the groups. We used linear regression models to investigate how PSMD, MD, and FA correlate with conventional neuroimaging markers of cSVD and cognitive scores in CAA.
Results
UNASSIGNED
PSMD was comparable in probable-CAA (median 4.06 × 10
Conclusion
UNASSIGNED
PSMD is a promising biomarker of cognitive impairment in CAA that outperforms other conventional and DTI-based neuroimaging markers. Although global PSMD is similarly increased in different forms of cSVD, PSMD's spatial variations could potentially provide insights into the predominant type of underlying microvascular pathology.
Identifiants
pubmed: 36440281
doi: 10.3389/fnins.2022.1051038
pmc: PMC9693722
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1051038Subventions
Organisme : NIA NIH HHS
ID : P30 AG062421
Pays : United States
Informations de copyright
Copyright © 2022 Zanon Zotin, Schoemaker, Raposo, Perosa, Bretzner, Sveikata, Li, van Veluw, Horn, Etherton, Charidimou, Gurol, Greenberg, Duering, Santos, Pontes-Neto and Viswanathan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
JAMA. 1993 May 12;269(18):2386-91
pubmed: 8479064
Neuroimage Clin. 2020;27:102280
pubmed: 32521475
Stroke. 2008 Jul;39(7):1988-92
pubmed: 18436874
Arch Clin Neuropsychol. 1999 Feb;14(2):167-77
pubmed: 14590600
Front Neurol. 2019 Feb 13;10:81
pubmed: 30814973
Neuroimage. 2014 Mar;88:79-90
pubmed: 24269273
Alzheimers Dement (Amst). 2019 Feb 26;11:191-204
pubmed: 30859119
Ann Neurol. 2019 Aug;86(2):279-292
pubmed: 31152566
J Cereb Blood Flow Metab. 2016 Jan;36(1):40-54
pubmed: 25944592
Stroke. 2015 Jan;46(1):255-7
pubmed: 25468879
J Gerontol. 1992 May;47(3):P154-8
pubmed: 1573197
Mult Scler Relat Disord. 2019 Jan;27:294-297
pubmed: 30448470
J Int Neuropsychol Soc. 2009 May;15(3):438-50
pubmed: 19402930
Neurology. 2015 Mar 24;84(12):1206-12
pubmed: 25716356
Alzheimers Dement (Amst). 2019 Oct 25;11:721-729
pubmed: 31700990
Neuroimage. 2015 Nov 15;122:166-76
pubmed: 26236030
J Cereb Blood Flow Metab. 2018 Feb;38(2):241-249
pubmed: 28318355
Front Neurosci. 2020 Mar 19;14:238
pubmed: 32265640
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
Ann Neurol. 2011 Feb;69(2):320-7
pubmed: 21387377
Neurology. 2018 Jan 9;90(2):e119-e126
pubmed: 29247070
Neurology. 2014 Jul 8;83(2):182-8
pubmed: 24920857
Hum Brain Mapp. 2002 Nov;17(3):143-55
pubmed: 12391568
Ann Neurol. 2011 Dec;70(6):871-80
pubmed: 22190361
Ann Neurol. 2005 Sep;58(3):459-62
pubmed: 16130107
Lancet Neurol. 2017 Sep;16(9):730-740
pubmed: 28716371
Neuroimage. 1999 Feb;9(2):179-94
pubmed: 9931268
Neurology. 2010 Apr 27;74(17):1346-50
pubmed: 20421578
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Alzheimers Dement. 2020 Nov;16(11):1504-1514
pubmed: 32808747
Neurology. 2004 Nov 9;63(9):1606-12
pubmed: 15534243
J Clin Psychol. 1987 Jul;43(4):402-9
pubmed: 3611374
Neuroimage. 2006 Jul 15;31(4):1487-505
pubmed: 16624579
Front Psychiatry. 2019 Jul 26;10:524
pubmed: 31402877
Neurology. 2019 Feb 26;92(9):e933-e943
pubmed: 30700595
Arch Clin Neuropsychol. 2004 Sep;19(6):759-67
pubmed: 15288329
Cerebrovasc Dis. 2015;39(3-4):224-31
pubmed: 25823458
Int J Psychophysiol. 2020 May;151:70-79
pubmed: 32109499
Curr Opin Neurol. 2018 Feb;31(1):36-43
pubmed: 29084064
Alzheimers Dement. 2018 Jun;14(6):764-774
pubmed: 29406155
AJNR Am J Neuroradiol. 2021 May;42(5):875-881
pubmed: 33664113
Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):91-101
pubmed: 19474567
Brain. 2015 Jan;138(Pt 1):179-88
pubmed: 25367025
Neurology. 2014 Aug 26;83(9):794-800
pubmed: 25063759
Stroke. 2006 Jul;37(7):1759-64
pubmed: 16763176
Arch Clin Neuropsychol. 2004 Mar;19(2):203-14
pubmed: 15010086
Neuroimage. 2010 Feb 1;49(3):2366-74
pubmed: 19837181
Stroke. 1983 Nov-Dec;14(6):924-8
pubmed: 6658996
J Am Heart Assoc. 2019 Feb 5;8(3):e011288
pubmed: 30717612
Ann Neurol. 2016 Oct;80(4):581-92
pubmed: 27518166
J Clin Exp Neuropsychol. 1998 Dec;20(6):828-34
pubmed: 10484693
Front Psychiatry. 2020 May 04;11:342
pubmed: 32425831